Second Opinion x Confido Market Map - Agentic Market Map Ambulatory Provider Categories - April 2026
FreeAI agent market map for ambulatory care
FreeFree tier
About Second Opinion x Confido Market Map - Agentic Market Map Ambulatory Provider Categories - April 2026
Second Opinion, in partnership with Confido, published a market map (April 2026) of companies deploying AI agents in the ambulatory or outpatient setting. The map focuses on post-Series A vendors, specifically excluding those whose primary business is selling into healthcare systems. It was curated from submissions by venture capital investors, operators, and founders. The map includes a downloadable PNG and details upcoming webinars on AI in healthcare. The editors note that the map is not fully exhaustive and struggled with categorization of scribe agents.
Key Features
Curated by Second Opinion and Confido using network submissions from VCs, operators, and founders
Focuses on AI agents deployed in ambulatory or outpatient settings
Includes only post-Series A companies, excluding pre-seed/seed and health-system-focused vendors
Downloadable PNG of the market map
Categorization of scribe agents (roadmapping vs. live) acknowledged as challenging
Upcoming webinars on AI in healthcare (HIPAA and physician access)
Pros & Cons
Pros
- Comprehensive and curated by domain experts (Second Opinion and Confido)
- Directly sourced from a cross-section of VC investors, operators, and founders
- Includes a downloadable visual map for easy reference
- Transparent about limitations and categorization challenges
- Accompanied by relevant webinars on key healthcare AI topics
Cons
- Not fully exhaustive; pre-seed and seed-stage companies excluded
- Excludes vendors primarily selling to healthcare systems, limiting scope
- Scribe category categorization is acknowledged as imperfect
- Limited to a single point in time (April 2026) without a clear update cycle
Best For
Understanding the competitive landscape of AI agents in outpatient careIdentifying potential investment targets among post-Series A ambulatory AI companiesBenchmarking against peer companies deploying AI in outpatient settingsDiscovering vendor categories and emerging trends in ambulatory AI
FAQ
Is this market map exhaustive?
No, the editors explicitly state that no market map is fully exhaustive. The map focuses on companies deploying AI agents in the ambulatory/outpatient setting and generally post-Series A.
Does the map include pre-seed or seed-stage companies?
No, it excludes pre-seed and seed-stage companies due to the explosion of activity at those stages.
How can my company be added to the map?
The editors invite companies that fit the criteria to reach out before the next update.
Why are scribe agents singled out?
The editors note they struggled with the scribe category because some agents involve roadmapping exercises while others are live.